Robert Carrasquillo1, Kevin Chu2, Ranjith Ramasamy2. 1. Department of Urology, University of Miami Miller School of Medicine, 1120 NW 14th Street, 15th floor, Miami, FL, 33136, USA. rjcarras@gmail.com. 2. Department of Urology, University of Miami Miller School of Medicine, 1120 NW 14th Street, 15th floor, Miami, FL, 33136, USA.
Abstract
PURPOSE OF REVIEW: Hypogonadism and the treatment of low testosterone is increasingly a subject of medical inquiry and controversy. The few treatments that are FDA-approved such as testosterone topicals, injections, and pellets create significant demand from patients for treatments with more convenient means of administration, fewer adverse effects, and the ability to maintain male fertility. Off-label drugs are in abundant use for low testosterone, including selective estrogen receptor modulators, gonadotropins, and aromatase inhibitors. RECENT FINDINGS: In this review, we summarize the evidence in support of commonly used treatments for male hypogonadism, as well as discuss recent updates in the development of novel therapeutics. New therapies include nasal testosterone, new oral testosterone formulations, anabolic-androgenic steroids, and selective androgen receptor modulators.
PURPOSE OF REVIEW: Hypogonadism and the treatment of low testosterone is increasingly a subject of medical inquiry and controversy. The few treatments that are FDA-approved such as testosterone topicals, injections, and pellets create significant demand from patients for treatments with more convenient means of administration, fewer adverse effects, and the ability to maintain male fertility. Off-label drugs are in abundant use for low testosterone, including selective estrogen receptor modulators, gonadotropins, and aromatase inhibitors. RECENT FINDINGS: In this review, we summarize the evidence in support of commonly used treatments for male hypogonadism, as well as discuss recent updates in the development of novel therapeutics. New therapies include nasal testosterone, new oral testosterone formulations, anabolic-androgenic steroids, and selective androgen receptor modulators.
Authors: Sandro La Vignera; Rosita Angela Condorelli; Laura Cimino; Giorgio Ivan Russo; Giuseppe Morgia; Aldo E Calogero Journal: Aging Male Date: 2015-10-21 Impact factor: 5.892
Authors: Andrew R McCullough; Mohit Khera; Irwin Goldstein; Wayne J G Hellstrom; Abraham Morgentaler; Laurence A Levine Journal: J Sex Med Date: 2012-01-12 Impact factor: 3.802
Authors: Anthony Y Yin; Michelle Htun; Ronald S Swerdloff; Maruja Diaz-Arjonilla; Robert E Dudley; Sandra Faulkner; Rachelle Bross; Andrew Leung; Sima Baravarian; Laura Hull; James A Longstreth; Steven Kulback; Gregory Flippo; Christina Wang Journal: J Androl Date: 2011-04-07
Authors: Ericson Pereira; Samuel Jorge Moyses; Sérgio Aparecido Ignácio; Daniel Komarchewski Mendes; Diego Sgarbi da Silva; Everdan Carneiro; Ana Maria Trindade Grégio Hardy; Edvaldo Antônio Ribeiro Rosa; Patrícia Vida Cassi Bettega; Aline Cristina Batista Rodrigues Johann Journal: PLoS One Date: 2019-10-16 Impact factor: 3.240
Authors: John M Masterson; Jordan Cohen; Ruben Blachman-Braun; Graham L Machen; Jay Sandlow; Ranjith Ramasamy Journal: Transl Androl Urol Date: 2020-04